- Email: [email protected]
Recent Topics on Primary Bone and Soft Tissue Tumors and Metastatic Bone Tumors
Annals of Oncology 30 (Supplement 6): vi62, 2019 doi:10.1093/annonc/mdz368
EDUCATIONAL LECTURE 27 : RECENT TOPICS ON PRIMARY BONE AND SOFT TISSUE TUMORS AND METASTATIC BONE TUMORS Recent Topics on Primary Bone and Soft Tissue Tumors and Metastatic Bone Tumors
Hiroshi Urakawa Clinical Oncology and Chemotherapy, Nagoya University Hospital Background: Recently, some drugs such as Pazopanib, Eribulin and Trabectedin can be used for advanced soft tissue sarcoma in Japan, but there are still few drugs useful for primary bone and soft tissue tumors. In metastatic bone tumors, bone modifying agents such as Zoledronic acid and Denosumab reduce skeletal related events (SREs) and are used clinically. Methods: I summarize and comment on recent findings from meetings and papers on primary bone and soft tissue tumors and metastatic bone tumors. Results and Conclusion: A phase III study was conducted using Olaratumab in addition to Doxorubicin as a primary treatment for advanced soft tissue tumors. Olaratumab
plus Doxorubicin therapy did not show any advantage in the primary end point of survival in comparison with Doxorubicin alone. Infantile fibrosarcoma with the NTRK gene translocation and inflammatory myofibroblastic tumors with the ALK gene translocation are expected to obtain benefit from use of molecular target drugs. TRK inhibitors and ALK inhibitors have been used in clinical trials and some good results have been reported. Molecular targeting drugs have been used for advanced osteosarcoma as a second line treatment, and the median disease-free survival was relatively good at 4.0 months with Sorafenib, 16.4 weeks with Regorafenib, and 6.2 months with Cabozantinib. In metastatic bone tumors, an attempt has been made to extend the administration interval of Zoledronic acid, and the noninferiority of 12 weeks’ administration has been reported as compared with 4 weeks’ administration for the occurrence of SREs in breast cancer.
C The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. V
All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_6/mdz368/5582957 by University of Victoria user on 25 October 2019
EL27
EDUCATIONAL LECTURE 27 : RECENT TOPICS ON PRIMARY BONE AND SOFT TISSUE TUMORS AND METASTATIC BONE TUMORS Recent Topics on Primary Bone and Soft Tissue Tumors and Metastatic Bone Tumors
Hiroshi Urakawa Clinical Oncology and Chemotherapy, Nagoya University Hospital Background: Recently, some drugs such as Pazopanib, Eribulin and Trabectedin can be used for advanced soft tissue sarcoma in Japan, but there are still few drugs useful for primary bone and soft tissue tumors. In metastatic bone tumors, bone modifying agents such as Zoledronic acid and Denosumab reduce skeletal related events (SREs) and are used clinically. Methods: I summarize and comment on recent findings from meetings and papers on primary bone and soft tissue tumors and metastatic bone tumors. Results and Conclusion: A phase III study was conducted using Olaratumab in addition to Doxorubicin as a primary treatment for advanced soft tissue tumors. Olaratumab
plus Doxorubicin therapy did not show any advantage in the primary end point of survival in comparison with Doxorubicin alone. Infantile fibrosarcoma with the NTRK gene translocation and inflammatory myofibroblastic tumors with the ALK gene translocation are expected to obtain benefit from use of molecular target drugs. TRK inhibitors and ALK inhibitors have been used in clinical trials and some good results have been reported. Molecular targeting drugs have been used for advanced osteosarcoma as a second line treatment, and the median disease-free survival was relatively good at 4.0 months with Sorafenib, 16.4 weeks with Regorafenib, and 6.2 months with Cabozantinib. In metastatic bone tumors, an attempt has been made to extend the administration interval of Zoledronic acid, and the noninferiority of 12 weeks’ administration has been reported as compared with 4 weeks’ administration for the occurrence of SREs in breast cancer.
C The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. V
All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_6/mdz368/5582957 by University of Victoria user on 25 October 2019
EL27